标题
Efficacy and safety of alisporivir for the treatment of hepatitis C infection
作者
关键词
-
出版物
EXPERT OPINION ON PHARMACOTHERAPY
Volume -, Issue -, Pages 1-6
出版商
Informa UK Limited
发表日期
2018-12-22
DOI
10.1080/14656566.2018.1560424
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Direct antiviral agents (DAAs) - A new age in the treatment of hepatitis C virus infection
- (2018) Ulrich Spengler PHARMACOLOGY & THERAPEUTICS
- EASL Recommendations on Treatment of Hepatitis C 2016
- (2017) JOURNAL OF HEPATOLOGY
- Efficacy and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir with ribavirin for the treatment of HCV genotype 1b compensated cirrhosis in patients aged 70 years or older
- (2017) Anca Trifan et al. MEDICINE
- Hepatitis C Virus-Genotype 3: Update on Current and Emergent Therapeutic Interventions
- (2017) Steven W. Johnson et al. Current Infectious Disease Reports
- Hepatitis C virus resistance to the new direct-acting antivirals
- (2016) Isabella Esposito et al. Expert Opinion on Drug Metabolism & Toxicology
- Prevention and management of treatment failure to new oral hepatitis C drugs
- (2016) Laura Benítez-Gutiérrez et al. EXPERT OPINION ON PHARMACOTHERAPY
- Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: A randomized phase III study (ALLY-3+)
- (2016) Vincent Leroy et al. HEPATOLOGY
- The importance of resistance to direct antiviral drugs in HCV infection in clinical practice
- (2016) Christoph Sarrazin JOURNAL OF HEPATOLOGY
- Update on Current Evidence for Hepatitis C Therapeutic Options in HCV Mono-infected Patients
- (2016) Mark W. Hull et al. Current Infectious Disease Reports
- Randomised clinical trial: alisporivir combined with peginterferon and ribavirin in treatment-naïve patients with chronic HCV genotype 1 infection (ESSENTIAL II)
- (2015) S. Zeuzem et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Alisporivir plus ribavirin, interferon free or in combination with pegylated interferon, for hepatitis C virus genotype 2 or 3 infection
- (2015) Jean-Michel Pawlotsky et al. HEPATOLOGY
- All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study
- (2015) David R. Nelson et al. HEPATOLOGY
- Therapy for hepatitis C genotype 3: moving forward
- (2015) M. Buti et al. JOURNAL OF VIRAL HEPATITIS
- Treatment of hepatitis C in difficult-to-treat patients
- (2015) Peter Ferenci Nature Reviews Gastroenterology & Hepatology
- Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection
- (2015) Graham R. Foster et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Novel Cyclophilin Inhibitor CPI-431-32 Concurrently Blocks HCV and HIV-1 Infections via a Similar Mechanism of Action
- (2015) Philippe A. Gallay et al. PLoS One
- The Combination of Alisporivir plus an NS5A Inhibitor Provides Additive to Synergistic Anti-Hepatitis C Virus Activity without Detectable Cross-Resistance
- (2014) Udayan Chatterji et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Interferon-free therapies for chronic hepatitis C: toward a hepatitis C virus-free world?
- (2014) Ivan Gentile et al. Expert Review of Anti-Infective Therapy
- Cyclophilin Inhibitors Reduce Phosphorylation of RNA-Dependent Protein Kinase to Restore Expression of IFN-Stimulated Genes in HCV-Infected Cells
- (2014) Takuji Daito et al. GASTROENTEROLOGY
- Cyclophilin inhibition as potential therapy for liver diseases
- (2014) Nikolai V. Naoumov JOURNAL OF HEPATOLOGY
- Alisporivir with peginterferon/ribavirin in patients with chronic hepatitis C genotype 1 infection who failed to respond to or relapsed after prior interferon-based therapy: FUNDAMENTAL, a Phase II trial
- (2014) M. Buti et al. JOURNAL OF VIRAL HEPATITIS
- Sofosbuvir and Ribavirin in HCV Genotypes 2 and 3
- (2014) Stefan Zeuzem et al. NEW ENGLAND JOURNAL OF MEDICINE
- Hepatitis C NS5A protein: two drug targets within the same protein with different mechanisms of resistance
- (2014) Precious J Lim et al. Current Opinion in Virology
- Novel Therapeutic Approaches for Hepatitis C
- (2013) J S Au et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Emerging treatments for hepatitis C
- (2013) Robert Flisiak et al. EXPERT OPINION ON EMERGING DRUGS
- 821 INTERFERON (IFN)-FREE ALISPORIVIR (ALV) HAS A BETTER OVERALL SAFETY PROFILE COMPARED TO IFN-CONTAINING TREATMENT: A POOLED ANALYSIS OF THE ALV DEVELOPMENT PROGRAM
- (2013) L. Griffel et al. JOURNAL OF HEPATOLOGY
- Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) – NCT01514890
- (2013) Christophe Hézode et al. JOURNAL OF HEPATOLOGY
- Profile of alisporivir and its potential in the treatment of hepatitis C
- (2013) Philippe Gallay et al. Drug Design Development and Therapy
- Update on alisporivir in treatment of viral hepatitis C
- (2012) Robert Flisiak et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- 466 PREDICTORS OF SUSTAINED VIROLOGIC RESPONSE AMONG TREATMENT-NAIVE PATIENTS WITH HEPATITIS C VIRUS GENOTYPE 1 WHEN TREATED WITH BOCEPREVIR (BOC) PLUS PEGINTERFERON ALFA-2B/RIBAVIRIN (PR)
- (2011) K.R. Reddy et al. JOURNAL OF HEPATOLOGY
- The invaders and the barrier
- (2011) Jean-Michel Pawlotsky JOURNAL OF HEPATOLOGY
- Structural Basis for the Non-Immunosuppressive Character of the Cyclosporin A Analogue Debio 025
- (2010) Isabelle Landrieu et al. BIOCHEMISTRY
- Cyclosporine Inhibits a Direct Interaction between Cyclophilins and Hepatitis C NS5A
- (2010) Fiona Fernandes et al. PLoS One
- DEB025 (Alisporivir) Inhibits Hepatitis C Virus Replication by Preventing a Cyclophilin A Induced Cis-Trans Isomerisation in Domain II of NS5A
- (2010) Lotte Coelmont et al. PLoS One
- An evaluation of the cyclophilin inhibitor Debio 025 and its potential as a treatment for chronic hepatitis C
- (2009) Raf Crabbé et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- The cyclophilin inhibitor Debio 025 combined with PEG IFNα2a significantly reduces viral load in treatment-naïve hepatitis C patients
- (2009) Robert Flisiak et al. HEPATOLOGY
- Hepatitis C Virus NS5A Protein Is a Substrate for the Peptidyl-prolylcis/transIsomerase Activity of Cyclophilins A and B
- (2009) Xavier Hanoulle et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- The Isomerase Active Site of Cyclophilin A Is Critical for Hepatitis C Virus Replication
- (2009) Udayan Chatterji et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- 946 PK-PD MODELING OF VIRAL KINETICS DURING TREATMENT WITH DEBIO-025 PLUS PEGYLATED INTERFERON ALPHA-2A IN TREATMENT-NAIVE HCV PATIENTS
- (2009) E. Herrmann et al. JOURNAL OF HEPATOLOGY
- 95 EFFICACY AND SAFETY OF THE CYCLOPHILIN INHIBITOR DEBIO 025 IN COMBINATION WITH PEGYLATED INTERFERON ALPHA-2A AND RIBAVIRIN IN PREVIOUSLY NULL-RESPONDER GENOTYPE 1 HCV PATIENTS
- (2009) D.R. Nelson et al. JOURNAL OF HEPATOLOGY
- Critical Role of Cyclophilin A and Its Prolyl-Peptidyl Isomerase Activity in the Structure and Function of the Hepatitis C Virus Replication Complex
- (2009) Z. Liu et al. JOURNAL OF VIROLOGY
- The cyclophilin inhibitor Debio-025 shows potent anti-hepatitis C effect in patients coinfected with hepatitis C and human immunodeficiency virus
- (2008) Robert Flisiak et al. HEPATOLOGY
- Current and future management of chronic hepatitis C infection
- (2008) T J S Cross et al. POSTGRADUATE MEDICAL JOURNAL
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started